Sorry, you need to enable JavaScript to visit this website.

Avelumab In Combination Treatments in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (Javelin DLBCL)

Phase 1b/Phase 3 Multicenter Study of Avelumab (MSB0010718C) in Combination Regimens That Include an
Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Category & Conditions: Cancer
Medicine: Bavencio (avelumab) PF-05082566
ClinicalTrials.gov Identifier (NCT): NCT02951156
Protocol ID: B9991011
    Share
PrintDownload
Open Plain Language Summary Result: Click here